−0.08 EUR
−3.68 M EUR
1.82 M EUR
32.80 M
About THERACLION
Sector
Industry
CEO
Martin Deterre
Website
Headquarters
Malakoff
Founded
2004
ISIN
FR0010120402
FIGI
BBG01C1F1P19
Théraclion SA develops, manufactures, and markets oncological medical equipment. Its products are marketed under the brands of Sonovein, EchoPulse and EPack. EchoPulse is a device used for non-invasive and outpatient treatment of fibroadenoma of the breast and thyroid nodules. EPack is a single-use disposable patented system used for cooling and coupling functions. The company was founded by François Lacoste and Jérôme Lebon on August 5, 2004 and is headquartered in Malakoff, France.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 941 is 0.26 EUR — it has decreased by −0.76% in the past 24 hours. Watch THERACLION stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange THERACLION stocks are traded under the ticker 941.
941 stock has risen by 22.54% compared to the previous week, the month change is a −34.75% fall, over the last year THERACLION has showed a −51.85% decrease.
941 stock is 24.64% volatile and has beta coefficient of 0.58. Track THERACLION stock price on the chart and check out the list of the most volatile stocks — is THERACLION there?
Today THERACLION has the market capitalization of 12.09 M, it has increased by 6.00% over the last week.
Yes, you can track THERACLION financials in yearly and quarterly reports right on TradingView.
941 net income for the last half-year is −2.36 M EUR, while the previous report showed −1.20 M EUR of net income which accounts for −97.11% change. Track more THERACLION financial stats to get the full picture.
No, 941 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. THERACLION EBITDA is −2.90 M EUR, and current EBITDA margin is −161.84%. See more stats in THERACLION financial statements.
Like other stocks, 941 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade THERACLION stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So THERACLION technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating THERACLION stock shows the strong sell signal. See more of THERACLION technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.